issued shares in Indo Rama Synthetics (India) Limited (“IRSL”), equaling to approximately 31.79% of IRSL’s enlarged share capital (the “Share Purchase”) at the price of INR 36 per share. The Company would

by its indirect subsidiary Indorama Netherlands B.V. (“INBV”) of 83,000,000 newly issued shares in Indo Rama Synthetics (India) Limited (“IRSL”), equaling to approximately 31.79% of IRSL’s enlarged

or 22.90% over the same period of last year of which hospital revenues totally raised by 10.16% along with the enlarged customer base of Subsidiary (AMARC) showing 15.67% of revenues’ growth. In

year, the Company has not yet earned income from Excellence Center (New Building) planned to official grand opening in the following year of February 2018) along with the enlarged customer base of the

baht, respectively. It increase 151.26 million baht or 31.10% when compared with Q3/2020. The reason for the increase income as a result increased sales of foreign products, the company has expanded the

shareholders, and subscribe Phoenix’s newly issued shares of 180.00 million shares, totaling 314.60 million shares or 55 percent of total enlarged shares of Phoenix. List of shareholders before and after

performance in 2nd quarter and 6-month period, its cost of services amounted to Baht 21.3 million and Baht 45.4 million, a rise of 12.4% and 20.5% whereas its selling & administrative expenses enlarged at

main factor that company increased the net profit was expanded the market and increased new clients. It could let the revenue increased by 9% (6% from Asia region, 2% from Europe region and 1% from

main factor that company increased the net profit was expanded the market and increased new clients. It could let the revenue increased by 9% (6% from Asia region, 2% from Europe region and 1% from

reason for the increase in income came from the company having increased sales of foreign products, the company has expanded the market to the United States and the European Union because there is a